Status:
RECRUITING
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
Lead Sponsor:
iOMEDICO AG
Conditions:
Esophageal Squamous Cell Carcinoma
Gastric Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intentio...
Detailed Description
SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic ...
Eligibility Criteria
Inclusion
- Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC
- Planned palliative systemic first-line therapy
- Age \>= 18 years
- Signed informed consent (IC)
- Patients answering questionnaires: IC before first therapy cycle
- Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle
Exclusion
- No systemic therapy for ESCC, EAC, GAC or GEJAC
Key Trial Info
Start Date :
December 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
1900 Patients enrolled
Trial Details
Trial ID
NCT04290806
Start Date
December 4 2019
End Date
December 31 2028
Last Update
January 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple sites, Gemany
Multiple Locations, Germany